MDWatch is a telehealth provider built around seniors on Medicare, combining low flat-rate compounded GLP-1s with the $50 Medicare Bridge Program and included lab monitoring.
Overview
Most GLP-1 telehealth is built for commercially insured or self-pay adults under 65. MDWatch inverts that, focusing on seniors on Medicare, a group that has historically had the worst options in this market because Medicare did not cover weight-loss medication.
It works both sides of the problem. For patients who qualify, it participates in the Medicare GLP-1 Bridge Program, giving access to Wegovy, the Zepbound KwikPen or Foundayo at a $50 monthly copay. For those who do not qualify or prefer compounded, it publishes compounded semaglutide at $90 and compounded tirzepatide at $140 per four-week supply, flat at every dose and on every refill, with no membership or subscription fees ever.
The clinical wrapper is more substantial than the price suggests. MDWatch publishes a free 15-minute initial consultation, monthly video visits included in the program, board-certified doctors and nurse practitioners, and genuine lab monitoring: baseline labs before treatment and a metabolic panel every six months, offered as an at-home kit with prepaid return envelopes or through a local lab.
MDWatch at a Glance
| Detail | What MDWatch Publishes |
|---|---|
| Type of company | Medicare-focused GLP-1 telehealth provider |
| Compounded semaglutide | $90 per 4-week supply |
| Compounded tirzepatide | $140 per 4-week supply |
| Medicare Bridge Program | $50 monthly copay for Wegovy, Zepbound KwikPen or Foundayo |
| Pricing model | Flat at every dose and on every refill |
| Labs | Baseline plus metabolic panel every 6 months, at-home kits available |
| States served | Licensed in 36 states, with waitlists elsewhere |
Medications Offered
- Compounded semaglutide, $90 per 4-week supply
- Compounded tirzepatide, $140 per 4-week supply
- Brand-name Wegovy via the Medicare Bridge Program at a $50 monthly copay
- Brand-name Zepbound KwikPen via the Medicare Bridge Program
- Brand-name Foundayo (orforglipron) via the Medicare Bridge Program
Brand-Name or Compounded?
Both routes are offered, and the distinction is handled clearly. Compounded semaglutide and tirzepatide come from licensed United States compounding pharmacies and are not FDA-approved, and MDWatch states plainly that compounded medications are not covered by Medicare or private insurance. Brand-name medication comes through the [Medicare GLP-1 Bridge Program](/articles/medicare-glp1-bridge-program) for eligible patients.
Consultation Process
Free consultation
Start with a free 15-minute initial consultation to see whether you qualify.
Baseline labs
Complete initial baseline labs, either through an at-home kit with a prepaid return envelope or at a local lab.
Choose your route
Eligible Medicare patients can use the Bridge Program at a $50 copay; others use flat-rate compounded medication.
Ongoing monitoring
Monthly video visits are included, with a metabolic panel every six months.
Eligibility
- Primary focus on seniors aged 65 and over on Medicare
- Compounded medication available to those who medically qualify after consultation
- Brand-name access requires Medicare Bridge Program eligibility
- Licensed in 36 states, with waitlists in several others
- Standard GLP-1 contraindications apply as assessed by the prescriber
Provider Involvement and Lab Requirements
Provider Involvement
Board-certified doctors and nurse practitioners, all licensed United States providers, delivering telehealth care. Monthly video visits are included in the program rather than billed separately, which supports ongoing titration and monitoring.
Lab Requirements
MDWatch includes genuine lab monitoring, which is rare at this price point. Initial baseline labs are required before treatment, and a metabolic panel follows every six months. Labs are offered as an at-home kit with prepaid return envelopes, or you can use a local lab.
Pharmacy Fulfillment and Shipping
Pharmacy Fulfillment
Licensed United States compounding pharmacies prepare the compounded medication, shipped to your door with tracking. Brand-name medication through the Bridge Program can be picked up at a local pharmacy or delivered to your home depending on eligibility.
Shipping Frequency
Compounded medication ships to your door with tracking on a four-week cadence, matching the supply size. Brand-name Bridge Program fills follow that program's rules, which cover 28-day or 30-day supplies only.
Support Services
- Free 15-minute initial consultation
- Monthly video visits included in the program
- Baseline and six-monthly lab monitoring included
- At-home lab kits with prepaid return envelopes
- No membership or subscription fees
Pricing
MDWatch publishes flat pricing that does not change as you titrate or refill, alongside the Medicare Bridge Program copay for brand-name medication.
| Plan or Medication | Published Price | What It Covers |
|---|---|---|
| Compounded semaglutide | $90 per 4-week supply | Same price at every dose and on every refill |
| Compounded tirzepatide | $140 per 4-week supply | Same price at every dose and on every refill |
| Medicare Bridge Program | $50 monthly copay | Wegovy, Zepbound KwikPen or Foundayo for eligible Medicare patients |
| Initial consultation | Free | 15-minute consultation before you commit |
| Membership or subscription | None | MDWatch publishes no membership or subscription fees, ever |
Pricing reflects what MDWatch published at the time of review and can change without notice. Confirm current pricing directly with the provider before enrolling.
Membership Fees
None. MDWatch states there are no membership or subscription fees, ever, and includes monthly video visits in the program price rather than charging separately.
Medication Fees
Compounded semaglutide is $90 per four-week supply and compounded tirzepatide $140, both flat at every dose and on every refill. Eligible Medicare patients pay a $50 monthly copay for brand-name medication through the Bridge Program.
Cancellation and Refund Policy
Cancellation
MDWatch publishes cancel anytime with no annual contracts for its compounded medications, which avoids the prepaid-year lock-in common elsewhere in this market.
Refunds
Specific refund terms are not detailed beyond the cancel-anytime position. Because the initial consultation is free, the main risk of paying to be declined is already removed. Request written terms for other scenarios.
Insurance, HSA and FSA
Insurance
MDWatch is explicit about the split. Medicare helps cover care visits and monitoring, but compounded medications are not covered by Medicare or private insurance. Brand-name medication is accessible at a $50 copay through the Medicare Bridge Program for eligible patients.
HSA / FSA
HSA and FSA acceptance is not stated. Confirm directly if you plan to pay from one of these accounts, though Medicare-age patients are less likely to hold an active FSA.
For a fuller explanation of how these accounts work with GLP-1 care, see our GLP-1 insurance, HSA and FSA guide.
Who MDWatch May Be Best For
- You are on Medicare and want a provider that understands that
- You want the cheapest published compounded pricing with no dose escalation
- You want genuine lab monitoring included rather than skipped
- You want a free consultation before committing
- You may qualify for the $50 Medicare Bridge Program
- Licensed in 36 states, with waitlists elsewhere
- Compounded medication is not covered by Medicare or private insurance
- Detailed refund terms are not published
- HSA and FSA acceptance is not stated
- Program design is oriented to seniors
Alternatives to Consider
Amazon Pharmacy
Also runs the $50 Medicare Bridge Program, with nationwide delivery.
Klinic
Brand-name telehealth that bills Medicare Part D directly, across all 50 states.
CoreAge Rx
Our top-rated pick if you are not on Medicare.
Precision Telemed
Also flat-rate across doses, available in all 50 states.
You can also compare the whole field in our GLP-1 provider comparison and best online GLP-1 providers roundups.
Frequently Asked Questions
How much does MDWatch cost?
Compounded semaglutide is $90 per four-week supply and compounded tirzepatide $140, flat at every dose and refill. Eligible Medicare patients pay a $50 monthly copay for brand-name medication through the Bridge Program. The initial consultation is free.
Does MDWatch work with Medicare?
Yes, and that is its focus. Medicare helps cover care visits and monitoring, and MDWatch participates in the [Medicare GLP-1 Bridge Program](/articles/medicare-glp1-bridge-program) giving eligible patients Wegovy, the Zepbound KwikPen or Foundayo at a $50 monthly copay.
Are labs included?
Lab monitoring is built into the program: baseline labs before treatment and a metabolic panel every six months. MDWatch offers at-home kits with prepaid return envelopes, or you can use a local lab.
Does the price rise as my dose increases?
No. MDWatch publishes the same price at every dose and the same price for all refills, which avoids the titration cost escalation common among compounded providers.
Is MDWatch available in my state?
MDWatch publishes licensing in 36 states with waitlists in several others, and says it is expanding regularly. Confirm your state before starting.
Does Medicare cover the compounded medication?
No. MDWatch states plainly that compounded medications are not covered by Medicare or private insurance. Medicare helps with care visits and monitoring, and the Bridge Program covers brand-name medication for eligible patients.
Medical Disclaimer
This review is for general information only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who knows your history can decide whether any medication is appropriate for you. Never start, stop, or change a prescription based on this page. If you have a medical emergency, call 911.
Details on this page describe what MDWatch published at the time of review. Programs, pricing, pharmacy partners, and policies change; verify everything directly with the provider before enrolling. See our full medical disclaimer.
Date reviewed: August 25, 2026